🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s AVDL Holdings & Trades

First Buy
Q1 2017
Duration Held
36 Quarters
Largest Add
Q2 2017
+686,373 Shares
Current Position
273,600 Shares
$5.9 M Value

Renaissance Technologies (RenTech)'s AVDL Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 273,600 shares of Avadel Pharmaceuticals plc (AVDL) worth $5.9 M, representing 0.01% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 36 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in AVDL, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2017, adding 686,373 shares. Largest reduction occurred in Q3 2018, reducing 469,935 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Avadel Pharmaceuticals plc (AVDL) Holding Value Over Time

Track share changes against reported price movement

Quarterly Avadel Pharmaceuticals plc (AVDL) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -282,500 Reduce 50.80% 273,600 $21.55
Q3 2025 +302,500 Add 119.28% 556,100 $15.27
Q2 2025 -87,400 Reduce 25.63% 253,600 $8.85
Q1 2025 -46,800 Reduce 12.07% 341,000 $7.83
Q4 2024 +366,300 Add 1703.72% 387,800 $10.51
Q3 2024 -42,896 Reduce 66.61% 21,500 $13.12
Q2 2024 -341,610 Reduce 84.14% 64,396 $14.06
Q1 2024 -219,100 Reduce 35.05% 406,006 $16.89
Q4 2023 -113,800 Reduce 15.40% 625,106 $14.12
Q3 2023 +46,800 Add 6.76% 738,906 $10.30
Q2 2023 -127,648 Reduce 15.57% 692,106 $0.02
Q1 2023 +133,948 Add 19.53% 819,754 $0.01
Q4 2022 -103,100 Reduce 13.07% 685,806 $0.01
Q3 2022 -65,100 Reduce 7.62% 788,906 $5.01
Q2 2022 +99,700 Add 13.22% 854,006 $2.44
Q1 2022 -91,500 Reduce 10.82% 754,306 $6.83
Q4 2021 -7,500 Reduce 0.88% 845,806 $8.08
Q3 2021 -23,200 Reduce 2.65% 853,306 $9.80
Q2 2021 -52,800 Reduce 5.68% 876,506 $6.73
Q1 2021 -117,000 Reduce 11.18% 929,306 $9.04
Q4 2020 -190,377 Reduce 15.39% 1.05 M $6.68
Q3 2020 -101,808 Reduce 7.61% 1.24 M $5.04
Q2 2020 +432,685 Add 47.77% 1.34 M $8.08
Q1 2020 +51,800 Add 6.07% 905,806 $7.94
Q4 2019 +32,000 Add 3.89% 854,006 $7.55
Q3 2019 +19,400 Add 2.42% 822,006 $4.16
Q2 2019 +144,270 Add 21.91% 802,606 $2.89
Q1 2019 +36,836 Add 5.93% 658,336 $1.44
Q4 2018 +42,365 Add 7.32% 621,500 $2.58
Q3 2018 -469,935 Reduce 44.80% 579,135 $4.39
Q2 2018 +267,270 Add 34.19% 1.05 M $6.13
Q1 2018 -362,800 Reduce 31.70% 781,800 $7.29
Q4 2017 +320,900 Add 38.96% 1.14 M $8.20
Q3 2017 +125,427 Add 17.96% 823,700 $10.50
Q2 2017 +686,373 Add 5767.84% 698,273 $11.03
Q1 2017 +11,900 New Buy 11,900 $9.66

Renaissance Technologies (RenTech)'s Avadel Pharmaceuticals plc Investment FAQs

Renaissance Technologies (RenTech) first purchased Avadel Pharmaceuticals plc (AVDL) in Q1 2017, acquiring 11,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Avadel Pharmaceuticals plc (AVDL) for 36 quarters since Q1 2017.

Renaissance Technologies (RenTech)'s largest addition to Avadel Pharmaceuticals plc (AVDL) was in Q2 2017, adding 698,273 shares worth $7.7 M.

According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 273,600 shares of Avadel Pharmaceuticals plc (AVDL), valued at approximately $5.9 M.

As of the Q4 2025 filing, Avadel Pharmaceuticals plc (AVDL) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Avadel Pharmaceuticals plc (AVDL) was 1,338,491 shares, as reported at the end of Q2 2020.